In M&A news, PRA International announced that funds managed by KKR are acquiring PRA International, the clinical research organization (CRO), from Genstar Capital.
PRA is one of the world’s leading global CRO, providing outsourced clinical development services to the biotechnology and pharmaceutical industries, according to the M&A news.
PRA has more than 5,300 employees located in over 50 offices worldwide.
Since 2000, PRA has performed approximately 2,000 clinical trials in over 80 countries on behalf of over 300 clients.
The M&A news transaction, which is subject to regulatory approvals and other customary closing conditions, is expected to close in the third quarter of 2013.
PRA International is a leading international CRO with over 5,300 employees offering services in 80+ countries.
The company provides services on a contract basis to the pharmaceutical and biotechnology industries, according to the M&A news.
PRA offers comprehensive services including the filing of Investigational New Drug and similar regulatory applications, management and implementation of Phase I through IV clinical trials, preparation and submission of New Drug Applications, and post-marketing surveillance on an international basis.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity